Stories of Progress

Where Science Meets Generosity

Each story here represents the intersection of scientific ambition and philanthropic vision. Donor investments at VMBHRC don't just fund experiments — they catalyze breakthroughs, unlock federal grants, and change the trajectories of patients' lives.

BreakthroughApril 2026

First FDA-Approved Gene Therapy for Genetic Hearing Loss

In April 2026, the FDA approved Otarmeni — the first gene therapy for OTOF-related congenital hearing loss, a condition caused by mutations in the otoferlin gene that leaves children profoundly deaf from birth. VMBHRC researchers including Dr. Rubinstein and Dr. Phillips contributed foundational expertise in cochlear physiology and implant candidacy evaluation that informed how gene therapy candidates were identified and trialed. The approval marks a historic moment: a child born deaf due to a single genetic mutation can now be treated with a targeted biological intervention rather than lifelong device dependence. This breakthrough reflects the power of combining basic research, clinical expertise, and philanthropic investment over years of sustained effort.

Donor Impact2024

Whitcraft Family Gift Unlocks 5-Year NIH Grant for Stone Lab

When the Whitcraft family made a generous pilot grant to Dr. Jennifer Stone's hair cell regeneration laboratory, they did far more than fund a single set of experiments. The resulting pilot data — showing that a specific molecular pathway could be modulated to extend the window of hair cell regeneration in mammals — formed the scientific core of a successful 5-year R01 application to the National Institutes of Health. For every philanthropic dollar invested, multiple federal dollars followed, dramatically amplifying the impact of the original gift. The Whitcraft family's story illustrates a pattern seen repeatedly at VMBHRC: private philanthropy takes the risks that federal agencies cannot, generating the evidence needed to unlock much larger pools of public research funding.

CampaignMarch 2026

Edwin W Rubel Trainee Endowment Campaign Launched

In March 2026, VMBHRC launched a campaign to establish a permanent trainee endowment honoring Dr. Edwin W Rubel, the Chair Emeritus whose decades of leadership built VMBHRC into one of North America's premier hearing research centers. The endowment is designed to bridge funding gaps that postdoctoral researchers and advanced graduate students face during transitions between grants — the periods when brilliant trainees are most at risk of leaving academia. Dr. Rubel's mentorship shaped a generation of hearing scientists now leading labs around the world, and this endowment will extend that legacy permanently. Contributions of all sizes are welcome, with naming recognition available for donors who establish named awards within the fund.

RecognitionAugust 2023

H&M Kellogg Trust Gift Earns UW Laureate Recognition

In August 2023, a transformative gift from the H&M Kellogg Trust in support of hair cell regeneration research at VMBHRC was recognized with UW's Laureate designation — one of the university's highest philanthropic honors. UW President Ana Mari Cauce wrote personally to acknowledge the Kellogg Trust's confidence in the work of Dr. Stone and Dr. Raible, whose research on molecular mechanisms of hair cell regeneration is among the most cited in the field. The gift directly funded pilot experiments that generated the data underlying multiple successful NIH grant applications. This recognition underscores how private philanthropy at the highest level catalyzes the entire research enterprise, from individual experiments to national funding priorities.

Facility2023

A Decade of Giving Transforms the VMBHRC Conference Room

Over the decade from 2014 to 2023, donors contributed a cumulative $416,664 to upgrade VMBHRC's shared conference and collaboration space — the physical hub where scientists present data, trainees receive mentorship, and visiting scholars meet their UW colleagues. The renovated space now features a 75-inch 4K display for high-resolution data presentation, a Kaptivo digital whiteboard system for capturing and sharing handwritten brainstorming, and a 12-seat custom conference table that comfortably accommodates lab meetings and donor visits alike. The before-and-after transformation is visible not just in the furniture and technology but in the quality of collaboration the space now enables. Facility investments like this one remind us that world-class science depends on world-class environments.

2026 Milestone

In 2026, our researchers helped achieve the first FDA-approved gene therapy for genetic hearing loss — a once-unimaginable milestone now reality.

This breakthrough was built on decades of basic science, clinical expertise, and the philanthropic courage to fund ideas before they were proven.